Risk of cardiovascular,cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease(NAFLD)has emerged as a public health problem of epidemic proportions worldwide.Accumulating clinical and epidemiological evidence indicates that NAFLD is not only associated with liver-related morbidity and mortality but also with an increased risk of coronary heart...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 20; no. 7; pp. 1724 - 1745
Main Author Ballestri, Stefano
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Co., Limited 21.02.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Non-alcoholic fatty liver disease(NAFLD)has emerged as a public health problem of epidemic proportions worldwide.Accumulating clinical and epidemiological evidence indicates that NAFLD is not only associated with liver-related morbidity and mortality but also with an increased risk of coronary heart disease(CHD),abnormalities of cardiac function and structure(e.g.,left ventricular dysfunction and hypertrophy,and heart failure),valvular heart disease(e.g.,aortic valve sclerosis)and arrhythmias(e.g.,atrial fibrillation).Experimental evidence suggests that NAFLD itself,especially in its more severe forms,exacerbates systemic/hepatic insulin resistance,causes atherogenic dyslipidemia,and releases a variety of pro-inflammatory,pro-coagulant and pro-fibrogenic mediators that may play important roles in the pathophysiology of cardiac and arrhythmic complications.Collectively,these findings suggest that patients with NAFLD may benefit from more intensive surveillance and early treatment interventions to decrease the risk for CHD and other cardiac/arrhythmic complications.The purpose of this clinical review is to summarize the rapidly expanding body of evidence that supports a strong association between NAFLD and cardiovascular,cardiac and arrhythmic complications,to briefly examine the putative biological mechanisms underlying this association,and to discuss some of the current treatment options that may influence both NAFLD and its related cardiac and arrhythmic complications.
Bibliography:Stefano Ballestri;Amedeo Lonardo;Stefano Bonapace;Christopher D Byrne;Paola Loria;Giovanni Targher;Division of Internal Medicine,Pavullo Hospital,41026 Pavullo,Italy;Department of Biomedical,Metabolic and Neural Sciences,Division of Internal Medicine NOCSAE,University of Modena and Reggio Emilia and Azienda USL,Baggiovara,41126 Modena,Italy;Division of Cardiology,"Sacro Cuore" Hospital,37024 Negrar,Italy;Southampton National Institute for Health Research Biomedical Research Centre,University Hospital Southampton,Southampton SO16 6YD,United Kingdom;Division of Endocrinology,Diabetes and Metabolism,Department of Medicine,University and Azienda Ospedaliera Universitaria Integrata,37126 Verona,Italy
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Author contributions: Targher G conceived the hypothesis and the outline of the manuscript; Ballestri S, Lonardo A and Targher G researched the data, analyzed the data and wrote the manuscript; Bonapace S, Byrne CD and Loria P contributed to discussion and reviewed/edited the manuscript.
Correspondence to: Giovanni Targher, MD, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata, Piazzale A. Stefani 1, 37126 Verona, Italy. giovanni.targher@univr.it
Telephone: +39-45-8123748 Fax: +39-45-8027314
ISSN:1007-9327
2219-2840
2219-2840
DOI:10.3748/wjg.v20.i7.1724